As a general rule we avoid individual cancer drugs, particularly those in the early stages of development. One of reasons is that they are often new drugs to be "in combination" with existing very expensive therapies. The benefits are often limited and apply to small subset of the cancer patient population. Although these have value, it's not the kind of broad and sweeping advance we like to cover.
NKarta (NKTX) caught our eye because they are focused on a cancer therapy around NK cells which MD Anderson notes "kills cancer quickly with few side effects." In order . . .